Use of sirolimus (rapamycin) to treat refractory Crohn's disease

Gut

Volumn 57, Issue 9, 2008, Pages 1294-1296

  Massey, D C O ^a   Bredin, F ^a   Parkes, M ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; INFLIXIMAB; MARKER; METHOTREXATE; RAPAMYCIN;

ADULT; ARTICLE; AUTOPHAGY; CASE REPORT; CELL CULTURE; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE SEVERITY; ENDOSCOPY; FEMALE; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; RECTOVAGINAL FISTULA; TREATMENT RESPONSE;

ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COLONOSCOPY; CROHN DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SEVERITY OF ILLNESS INDEX; SIROLIMUS;

EID: 50249111131     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2008.157297     Document Type: Article

References (15)

1. Baert F. Noman M, Vermeire S, et al. Influence of immunogencity on the long-term efficacy of infliximab in Crohn's disease N Engl J Med 2003;348:601-8.
2. Cosnes J, Nion-Larmurier I, Beaugerie L et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005;54:734.
3. Hampe J, Franke A, Rosenstiel P, et al. A genome-wide association scan identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 2007;39:207-11.
4. Rioux JD, Xavier RJ, Taylor KD, et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet 2007;39:596-604.
5. The Wallcome Truct Case Control Consortium Genome-wide association study of 14.000 cases of seven common diseases and 3.000 shared controls. Nature 2007;447:661-78.
6. Parkas M, Barrett JC, Prescott NJ, et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet 2007;39:830-2.
7. Mathew CG. New links to the pathogenesis of Crohn disease provided by genome-wide association scans. Nat Rev Genet 2008;9:9-14.
8. Webster AC, Lee VW, Chapman JR. et al. Target of rapamycin inhibitors (sirolirmus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006;81(9):1234-48.
9. Zhu J, Wu J. Frizell E, et al. Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology 1999;117:1198-204.
10. Molinari M,AI-Saif F, Ryan EA, et al. Sirolirnus-induced ulceration of the small bowel in islet transplant recipients: report of two cases. Am J Transplant 2005;5:2799-804.
11. Smith AD, Bai D, Marroquin CE, et al. Gastrointestinal hemorrhage due to complicated gastroduodenal ulcer disease in liver transplant patients taking sirolimus. Clin Transplant 2005;19:250-4.
12. Ravikumar B, Vacher C. Berger Z. et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntingdon disease. Nat Genet 2004;39:585-95.
13. Singh SB, Davis AS. Taylor GA, et al. Human IRGM induces autophagy to eliminate intracellular mycobacteria. Science 2006;313:1433-41.
14. Rolhioa N, Darfeuille-Michaud A. Adherent-invasive Escherichina coli in inflammatory bowel disease. Inflamm Bowel Dis 2007;13:1277-83.
15. Dengjel J, Schoor O, Fischer R. et al. Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. Proc Natl Acad Sci U S A 2005;102:7922-7.